Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Seasonal Influenza Market Grown from 2024 to 2025?
The market size for seasonal influenza has seen swift enlargement in recent history. Projected growth figures indicate an increase from $8.41 billion in 2024 to $9.88 billion in 2025, indicating a compound annual growth rate (CAGR) of 17.4%. This significant growth during the historical period can be ascribed to several factors. These include an increase in cases of influenza, a growth in the aged population, an increase in the frequency of infectious and chronic diseases, a mounting impact of illnesses related to influenza, and a rise in respiratory infections.
What Growth Rate Is Anticipated for the Seasonal Influenza Market in the Coming Years?
It is anticipated that the market size for seasonal influenza will experience quick expansion in the coming years, reaching $18.55 billion in 2029 with a compound annual growth rate (CAGR) of 17.1%. The surge during the predictive period is due to a rising requirement for oral medication solutions, escalated R&D efforts, a growth in vaccine numbers, enhanced healthcare facilities, and a growing need for retail pharmacies. Key trends expected during the forecast period encompass progress in treatment methods, technological advancements, evolution in vaccine technology, mRNA technology, and digital health solutions for monitoring and diagnosis.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21285&type=smp
Who Are the Leading Companies in the Seasonal Influenza Market?
Major companies operating in the seasonal influenza market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Merck KGaA, Moderna Inc., Boehringer Ingelheim International GmbH, Sinovac Biotech Ltd., Daiichi Sankyo Company Limited, CSL Limited, Genentech Inc., Shionogi & Co. Ltd., Emergent BioSolutions Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Bharat Biotech International Limited, Vaxart Inc., Inovio Pharmaceuticals Inc., SK bioscience Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., Altimmune Inc.
What Are the Key Drivers of the Seasonal Influenza Market?
The rise in respiratory infections is set to fuel the expansion of the seasonal influenza market. These infections, resulting from viruses or bacteria, impact the respiratory system, encompassing the sinuses, throat, airways, or lungs. Factors contributing to the growing number of respiratory infections include air pollution, variations in climate, reduced immune responses, and the ease of spreading viruses in congested or inadequately ventilated spaces. The treatment for seasonal influenza provides various ways to avert or lessen the intensity of respiratory infections, mainly by targeting the influenza virus and managing the symptoms that can result in secondary infections. For example, the UK Health Security Agency, a government agency in the UK, reported that in October 2024, tuberculosis (TB) cases in England – a respiratory infection caused by the bacterium Mycobacterium tuberculosis – saw an annual increase of 10.7% in 2023, growing from 4,380 cases in 2022 to 4,850 cases. As such, the surge in respiratory infections is anticipated to foster the development of the seasonal influenza market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21285&type=smp
What Are the Key Market Segments in the Seasonal Influenza Industry?
The seasonal influenza market covered in this report is segmented –
1) By Type: Influenza A Virus, Influenza B Virus, Influenza C Virus, Influenza D Virus
2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations
3) By Distribution Channel: Hospital, Government and institutional supply, Pharmacy, Online
4) By Treatment: Antiviral, Neuraminidase Inhibitors, Vaccination, Other Treatments
Subsegments:
1) By Influenza A Virus: Subtype H1N1, Subtype H3N2, Other Subtypes
2) By Influenza B Virus: Lineage Victoria, Lineage Yamagata
3) By Influenza C Virus: Seasonal C Virus, Non-seasonal C Virus
4) By Influenza D Virus: Animal-associated Influenza D
What Are the Latest Trends in the Seasonal Influenza Market?
Leading firms operating in the seasonal influenza market are directing their efforts towards innovation in treatment methods, like combination vaccines, to bolster immunity by addressing multiple variants of the virus. This enhances the efficiency and downplays the requirement for regular vaccinations. Combination vaccines counteract multiple illnesses or different strains with just one inoculation, which brings down the count of jabs necessary for immunization. For instance, Moderna, Inc., an American biotech firm, made an announcement in October 2023, revealing encouraging early Phase 1/2 trial outcomes for mRNA-1083, their experimental combination vaccine tackling both flu and COVID-19. mRNA-1083 is designed to boost compliance, simplify management and enhance convenience for both individuals and healthcare systems. Currently, it’s being assessed for safety and ability to prompt an immune response in comparison to standard flu vaccines like Fluarix (for age group 50-64) and Fluzone HD (for age group 65-79), and also against the Spikevax booster.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/seasonal-influenza-global-market-report
What Are the Key Regional Markets in the Seasonal Influenza Industry?
North America was the largest region in the seasonal influenza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the seasonal influenza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21285
This Report Delivers Insight On:
1. How big is the seasonal influenza market, and how is it changing globally?
2. Who are the major companies in the seasonal influenza market, and how are they performing?
3. What are the key opportunities and risks in the seasonal influenza market right now?
4. Which products or customer segments are growing the most in the seasonal influenza market?
5. What factors are helping or slowing down the growth of the seasonal influenza market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model